Seminari di Ematologia Oncologica - Società Italiana di Ematologia

28 Seminari di Ematologia Oncologica
mortality rate than autologous transplantation. Bone
Marrow Transplant. 2003; 31: 667-78.
44. Kirsty Thomson KJ, Morris EC, Bloor A, Cook G,
Milligan D, Parker A, Clark F, Yung L, Linch DC,
Chakraverty R, Peggs KS, Mackinnon S. Favorable
long-term survival after reduced-intensity allogeneic
transplantation for multiple-relapse aggressive non-
Hodgkin's lymphoma. J Clin Oncol. 2009; 27: 426-32.
45. Czuczman MS, Vose JM, Zinzani PL, et al. Confirmation
of the efficacy and safety of lenalidomide oral
monotherapy in patients with relapsed or refractory diffuse
large-B cell lymphoma: results of an international
study (NHL-003). [Abstract] Blood. 112: 268.
46. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose
JM, Craig E, et al. Lenalidomide monotherapy in
relapsed or refractory aggressive non Hodgkin’s lymphoma.
J Clin Oncol 2008; 26: 4952-57.
47. Coso D, Sebban C, Boulat O, Biron P, Rey J, Aurran
T, et al. A phase II trial of rituximab as adjuvant to intensive
sequential chemotherapy in patients under 60
years with untreated poor-prognosis diffuse large Bcell
lymphoma. Bone Marrow Transplant 2006; 38 (3):
217-22.
48. Glass B, Kloess M, Bentz M, Schlimok G, Berdel WE,
Feller A, et al. Dose-escalated CHOP plus etoposide
(MegaCHOEP) followed by repeated stem cell transplantation
for primary treatment of aggressive highrisk
non-Hodgkin lymphoma. Blood 2006; 107 (8):
3058-64.
49. Intragumtornchai T, Bunworasate U, Nakorn TN,
Rojnuckarin P. Rituximab-CHOP-ESHAP vs CHOP-
ESHAP-high-dose therapy vs conventional CHOP
chemotherapy in high-intermediate and high-risk
aggressive non-Hodgkin's lymphoma. Leuk Lymphoma
2006; 47 (7): 1306-14.
50. Rueda A, Sabin P, Rifá J, Llanos M, Gómez-Codina J,
Lobo F, et al. R-CHOP-14 in patients with diffuse large
B-cell lymphoma younger than 70 years: a multicentre,
prospective study. Hematol Oncol 2008; 26 (1): 27-32.
51. Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie
L, Morris DG, et al. Upfront double high-dose
chemotherapy with DICEP followed by BEAM and
autologous stem cell transplantation for poor-prognosis
aggressive non-Hodgkin lymphoma. Blood 2006;
107 (12): 4623-27.
52. Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R,
Pescarollo A, et al. Prolonged survival in poor-risk diffuse
large B-cell lymphoma following front-line treatment
with rituximab-supplemented, early-intensified
chemotherapy with multiple autologous hematopoietic
stem cell support: a multicenter study by GITIL
(Gruppo Italiano Terapie Innovative nei Linfomi).
Leukemia 2007; 21 (8): 1802-11.
53. Arranz R, Conde E, Grande C, Mateos MV, Gandarillas
M, Albo C, et al. Dose-escalated CHOP and tailored
intensification with IFE according to early response and
followed by BEAM/autologous stem-cell transplantation
in poor-risk aggressive B-cell lymphoma: a
prospective study from the GEL-TAMO Study Group.
Eur J Haematol 2008; 80 (3): 227-35.
54. Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly
H, et al. Rituximab versus observation after high-dose
consolidative first-line chemotherapy with autologous
stem-cell transplantation in patients with poor-risk diffuse
large B-cell lymphoma. Ann Oncol 2009; 20 (12):
1985-92.